Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Post by sav22on Feb 05, 2014 10:33am

160 Views

Post# 22174154

New Information on Critical Outcome Technologies

Today, Critical Outcome Technologies Inc (CVE: COT) shares increased incredibly by $0.04 (19%) to $0.25 after learning about a news story. See Vernon Haroldson's interpretation Vernon Haroldson TickrWatch CVE: COT

Bullboard Posts

Canadian artificial intelligence ETFs